Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A Toll for lupus.

H J Anders1

  • 1Medical Policlinic, Ludwig-Maximilians-University, Munich, Germany. hjanders@med.uni-muenchen.de

Lupus
|July 26, 2005
PubMed
Summary
This summary is machine-generated.

Toll-like receptor (TLR)-9 recognizes microbial DNA, impacting immunity and autoimmunity like in systemic lupus erythematosus (SLE). This review explores TLR9

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Refractory lupus nephritis: a survey.

Lupus·2019
Same author

[A 68-year-old patient with atrial flutter/fibrillation, inadequate anticoagulation, subacute amaurosis, normal ESR, and lymphadenopathy].

Der Internist·2008
Same author

Diagnosis and management of crescentic glomerulonephritis: state of the art.

Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia·2008
Same author

[Chronic renal failure].

MMW Fortschritte der Medizin·2006
Same author

[Psoriatic onycho-pachydermo- periostitis].

Zeitschrift fur Rheumatologie·2002
Same author

[Urine diagnosis: proteinuria].

Deutsche medizinische Wochenschrift (1946)·2001
Same journal

Recent advances in the management of pediatric neuropsychiatric lupus from conventional therapies to novel immunomodulators.

Lupus·2026
Same journal

Association of serum and urinary galectin-3 with renal fibrosis in patients with lupus nephritis: A cross-sectional controlled study.

Lupus·2026
Same journal

Continuation of belimumab in patients with systemic lupus erythematosus in a real-world setting: A single-center retrospective cohort study.

Lupus·2026
Same journal

Unusual triad in systemic lupus erythematosus: Alopecia, pigmentation, and keratoderma.

Lupus·2026
Same journal

Serum RIPK3/MLKL as exploratory biomarker candidates for systemic lupus erythematosus.

Lupus·2026
Same journal

Clinical and histopathological predictors of systemic lupus erythematosus in a South American cohort of patients with full-house glomerulonephritis.

Lupus·2026
See all related articles

Area of Science:

  • Immunology
  • Molecular Biology
  • Rheumatology

Background:

  • Toll-like receptor (TLR)-9 identifies CpG motifs in microbial DNA, activating innate and adaptive immunity.
  • TLR9 signaling influences immune responses, including autoimmunity, as seen in systemic lupus erythematosus (SLE).

Purpose of the Study:

  • To review the role of TLR9 signaling in lupus pathogenesis.
  • To investigate TLR9's involvement in infection-induced lupus activity.
  • To assess risks associated with CpG motifs in vaccine adjuvants for SLE patients.
  • To determine if TLR9 recognizes self-DNA in lupus.

Main Methods:

  • Literature review of existing studies on TLR9 and lupus.
  • Analysis of data linking CpG-DNA/TLR9 interactions to disease activity.

Related Experiment Videos

  • Evaluation of immunological responses to vaccine adjuvants in lupus models.

    • Main Results:

    • TLR9 signaling is implicated in the pathogenesis of systemic lupus erythematosus.
    • CpG-DNA/TLR9 interactions may contribute to infection-induced lupus flare-ups.
    • The use of CpG motifs in vaccine adjuvants for lupus patients warrants careful consideration due to potential risks.

    Conclusions:

    • TLR9 signaling plays a significant role in the development and activity of systemic lupus erythematosus.
    • Further research is needed to fully elucidate the complex interplay between TLR9, self-DNA, microbial DNA, and lupus pathogenesis.
    • Clinical implications for vaccination strategies in SLE patients require careful evaluation of TLR9-activating adjuvants.